Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a double-blinded, placebo-controlled randomized phase II clinical trial investigating
whether flibanserin promotes sexual interest in men with prostate cancer who are receiving
androgen suppression.